Adventrx Turns Focus From CoFactor To Vinorelbine, Docetaxel After Phase IIb Failure In CRC
This article was originally published in The Pink Sheet Daily
Executive Summary
CoFactor/5-FU arm fails to demonstrate significantly improved safety over leucovorin/5-FU in treatment of metastatic colorectal cancer, but method of administration may make a difference, CEO says.
You may also be interested in...
Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure
Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.
Adventrx Finds Success In Vinorelbine Emulsion Study After CoFactor Failure
Firm is on track to submit ANX-530 505(b)(2) new drug application with data showing bioequivalence to GSK’S Navelbine in 2008.
Adventrx Halts Phase III Study Of CoFactor In Metastatic Colorectal Cancer
Further development of biomodulator depends heavily on results of a breast cancer study, expected in Q2 2008, CEO Levine says at BIOCOM Investor Conference.